Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.
复制标题
DOI：
10.3390/diagnostics11010098
复制
发表时间：
2021-01-09
期刊：
影响因子：
--
通讯作者：
Lonardo A
中科院分区：
文献类型：
--
作者：
Ballestri S;Mantovani A;Baldelli E;Lugari S;Maurantonio M;Nascimbeni F;Marrazzo A;Romagnoli D;Targher G;Lonardo A
肝纤维化可预测慢性肝病患者的肝相关和心血管预后。我们比较了不同的肝纤维化生物标志物的诊断性能，以确定组织学显着/晚期纤维化。此外，评估了此类肝纤维化生物标志物与心血管风险(CVR)评分的相关性。173例病毒性肝炎患者(其中丙型肝炎157例，乙肝16例)和107例非酒精性脂肪性肝病(NAFLD)患者连续入选。肝纤维化生物标志物：天冬氨酸氨基转移酶(AST)/丙氨酸氨基转移酶(ALT)比值(ARR)、AST/血小板比率指数(APRI)、纤维蛋白原-4(FIB-4)、Forns指数、NAFLD纤维化评分(NFS)、BARD(体重指数(BMI)、AAR、糖尿病)和肝纤维化评分(HFS)。CVR通过计分、Progetto CUORE或Framingham风险评分系统进行评估。无论慢性肝病的病因是什么，肝纤维化生物标志物在预测所有患者的晚期肝纤维化方面表现得更好，而不是显著的。Forns指数和HFS在预测病毒性慢性肝病和NAFLD患者的晚期纤维化方面表现最好。总体而言，这些肝纤维化生物标志物的较低截断值对晚期纤维化以及NAFLD或病毒性慢性肝病患者具有较高的阴性预测值。FIB-4、Forns指数、神经功能评分和HFS与评分和Framingham风险评分呈正相关。总之，在慢性肝病患者中，肝纤维化生物标志物准确地排除了晚期纤维化，并与CVR评分呈正相关。
Liver fibrosis predicts liver-related and cardiovascular outcomes in chronic liver disease patients. We compared the diagnostic performance of various liver fibrosis biomarkers for identifying histological significant/advanced fibrosis. Additionally, the correlations of such liver fibrosis biomarkers with cardiovascular risk (CVR) scores were evaluated. 173 patients with viral hepatitis (157 HCV and 16 HBV) and 107 with a non-alcoholic fatty liver disease (NAFLD) were consecutively enrolled. Various liver fibrosis biomarkers: aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (ARR), AST to Platelet Ratio Index (APRI), Fibrosis-4 (FiB-4), Forns index, NAFLD fibrosis score (NFS), BARD (body mass index (BMI), AAR, Diabetes) score, and Hepamet fibrosis score (HFS), were used to identify significant/advanced fibrosis. CVR was assessed by using the SCORE, the Progetto CUORE, or the Framingham risk scoring systems. Liver fibrosis biomarkers performed better in predicting advanced rather than significant liver fibrosis in all patients, regardless of chronic liver disease aetiology. Forns index and HFS performed best in predicting advanced fibrosis in patients with viral chronic liver disease and NAFLD. Lower cut-offs of these liver fibrosis biomarkers had high negative predictive values for advanced fibrosis overall, as well as in patients with NAFLD or viral chronic liver disease. FIB-4, Forns index, NFS, and HFS were positively correlated with SCORE and Framingham risk scores. In conclusion, liver fibrosis biomarkers accurately exclude advanced fibrosis and positively correlate with CVR scores in patients with chronic liver disease.
登录
查看更多内容
影响因子：
29.4
作者：
Cotter, Thomas G.;Rinella, Mary
通讯作者：
Rinella, Mary
影响因子：
5.3
作者：
Adinolfi, Luigi Elio;Petta, Salvatore;Craxi, Antonio
通讯作者：
Craxi, Antonio
冠状动脉疾病患者肝纤维化评分与死亡风险之间的关联
影响因子：
5.3
作者：
Chen, Qian;Li, Qing;Ling, Wenhua
通讯作者：
Ling, Wenhua
DOI：
10.1097/meg.0000000000001519
发表时间：
2020-03-01
影响因子：
2.1
作者：
Carli, Maria A. L. de;de Carli, Luiz A.;Coral, Gabriela P.
通讯作者：
Coral, Gabriela P.
影响因子：
29.4
作者：
Angulo P;Kleiner DE;Dam-Larsen S;Adams LA;Bjornsson ES;Charatcharoenwitthaya P;Mills PR;Keach JC;Lafferty HD;Stahler A;Haflidadottir S;Bendtsen F
通讯作者：
Bendtsen F